Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
Identifieur interne : 000021 ( PubMed/Curation ); précédent : 000020; suivant : 000022Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
Auteurs : Ruklanthi De Alwis [Singapour] ; Shiwei Chen [Singapour] ; Esther S. Gan [Singapour] ; Eng Eong Ooi [Singapour]Source :
- EBioMedicine [ 2352-3964 ] ; 2020.
Abstract
The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
DOI: 10.1016/j.ebiom.2020.102768
PubMed: 32344202
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000021
Links to Exploration step
pubmed:32344202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</title><author><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea></affiliation></author><author><name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea></affiliation></author><author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32344202</idno><idno type="pmid">32344202</idno><idno type="doi">10.1016/j.ebiom.2020.102768</idno><idno type="wicri:Area/PubMed/Corpus">000021</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000021</idno><idno type="wicri:Area/PubMed/Curation">000021</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000021</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</title><author><name sortKey="De Alwis, Ruklanthi" sort="De Alwis, Ruklanthi" uniqKey="De Alwis R" first="Ruklanthi" last="De Alwis">Ruklanthi De Alwis</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre</wicri:regionArea></affiliation></author><author><name sortKey="Chen, Shiwei" sort="Chen, Shiwei" uniqKey="Chen S" first="Shiwei" last="Chen">Shiwei Chen</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea></affiliation></author><author><name sortKey="Gan, Esther S" sort="Gan, Esther S" uniqKey="Gan E" first="Esther S" last="Gan">Esther S. Gan</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School</wicri:regionArea></affiliation></author><author><name sortKey="Ooi, Eng Eong" sort="Ooi, Eng Eong" uniqKey="Ooi E" first="Eng Eong" last="Ooi">Eng Eong Ooi</name><affiliation wicri:level="1"><nlm:affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore</wicri:regionArea></affiliation></author></analytic><series><title level="j">EBioMedicine</title><idno type="eISSN">2352-3964</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32344202</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><PubDate><Year>2020</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.</ArticleTitle><Pagination><MedlinePgn>102768</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30143-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.102768</ELocationID><Abstract><AbstractText>The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.</AbstractText><CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Alwis</LastName><ForeName>Ruklanthi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shiwei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Esther S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ooi</LastName><ForeName>Eng Eong</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore; Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: engeong.ooi@duke-nus.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Polyclonal hyperimmune globulin</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32344202</ArticleId><ArticleId IdType="pii">S2352-3964(20)30143-2</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2020.102768</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000021 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000021 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32344202
|texte= Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32344202" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |